• Avoid nephrotoxic drugs:
o NSAIDs: ↓ renal perfusion
o Aminoglycosides: ATN risk
o Lithium: narrow therapeutic index
o Metformin: risk of lactic acidosis if eGFR <30 mL/min
• Dose adjustment required for renally-excreted drugs:
o Low molecular weight heparin (LMWH)
o Digoxin
o Antibiotics: aminoglycosides, vancomycin, penicillins
• Avoid or reduce dose of hepatotoxic drugs:
o Paracetamol: increased risk of hepatotoxicity
o Statins, methotrexate, valproate
• Altered metabolism:
o ↓ cytochrome P450 function → drug accumulation
o ↑ risk with benzodiazepines, opioids, warfarin
• Monitor INR, albumin, bilirubin, and signs of encephalopathy
• Avoid known teratogens:
o ACE inhibitors: renal agenesis
o Warfarin: fetal warfarin syndrome
o Valproate: neural tube defects
• Safe alternatives:
o Hypertension: labetalol, nifedipine, methyldopa
o Diabetes: insulin preferred over oral hypoglycaemics
o Thyroid disease: propylthiouracil (1st trimester), carbimazole (2nd–3rd)
• Use Pregnancy Risk Categories and local guidelines
• Generally safe:
o Paracetamol, penicillins, cephalosporins, heparins
o Most vaccines (except yellow fever)
• Avoid:
o Amiodarone: thyroid dysfunction
o Lithium: toxicity
o Tetracyclines: teeth discolouration
o Chloramphenicol: “grey baby” syndrome
Elderly Patients
• Polypharmacy → ↑ risk of adverse drug reactions (ADRs), falls, hospitalisation
• Pharmacokinetic changes:
o ↓ renal function (check eGFR)
o ↓ hepatic metabolism
o ↓ albumin → ↑ free drug concentration (e.g. phenytoin, warfarin)
• Start low, go slow: careful dose titration
• Common culprits:
o Antibiotics: macrolides (e.g. erythromycin), quinolones
o Antipsychotics: haloperidol, risperidone
o Antidepressants: TCAs, SSRIs (e.g. citalopram)
o Antiarrhythmics: amiodarone, sotalol
• Risk: torsades de pointes → syncope, sudden death
• Check QTc on ECG if high-risk meds are prescribed
• Avoid combinations of QT-prolonging drugs
• Always check:
o Allergies
o Renal and hepatic function
o Drug interactions
o BNF/local guidelines
o Dose, route, and timing
• Use electronic prescribing systems and decision support tools
• Monitor therapeutic drug levels: e.g. lithium, digoxin, phenytoin
Principles of drug metabolism and interactions
Clinical pharmacology and prescribing in special situations
System-based theraputics and core drug classes
————————————————————————————————————————————————————————————————————————————————————————————————————————-
Author & Educational Disclaimer
Author:
Dr Phillip Cockrell BM FRCP DipClinEd
Dr Phillip Cockrell is a UK Consultant Physician in Internal Medicine, currently working at Queen Alexandra Hospital, Portsmouth University Hospitals NHS Trust. He has previously worked as a registrar across Intensive Care Medicine, Gastroenterology, Cardiology, Stroke Medicine, Acute Medicine, and Respiratory Medicine.
He has held senior leadership roles including Associate Clinical Director of the Acute Medical Unit, Clinical Director of Internal Medicine, and Chief of Medicine. Dr Cockrell has over 15 years’ experience in postgraduate medical education, having lectured extensively across the MRCP syllabus and contributed to MRCP revision teaching and course development.
Dr Cockrell holds a Bachelor of Medicine (BM), Fellowship of the Royal College of Physicians (FRCP), and a Diploma in Clinical Education (DipClinEd). His teaching approach is based on structured consolidation of complex medical topics to support efficient and effective revision for postgraduate examinations.
Purpose of this content:
The material on this page is intended solely for educational purposes to support revision for the MRCP (UK) Part 1 examination. It reflects examination-relevant principles of internal medicine and is designed to aid learning and pattern recognition.
Medical disclaimer:
This content is designed for postgraduate medical examination revision and does not constitute medical advice, diagnosis, or treatment guidance and must not be used as a substitute for professional clinical judgement, local guidelines, or specialist consultation. Clinical decisions should always be made in the context of individual patient circumstances and current national guidance.